News

The Treanda new drug application (NDA) for relapsed indolent non-Hodgkin’s lymphoma (NHL) is supported by three studies in patients with NHL, including one in combination with rituximab. In

The primary objective of this study is to evaluate the 1-year survival rate of three dosing schedules of sapacitabine in elderly patients with previously untreated or first relapsed

Cherokee has also entered into a five-year supply agreement with Merck for an estimated value of $100-200 million annually. The Cherokee plant is a active pharmaceutical ingredient manufacturing

Mr. Ocana has been associated with CytoCore for over a year. Prior to joining CytoCore, his previous positions include senior vice president and managing director at CH-Werfen, a

WorkstationOne is intended for softcopy reading and interpretation of digital mammography images, and was developed with the goal of assisting radiologists to read digital mammograms efficiently. WorkstationOne is

The clinical trial utilized an open-label, Simon two-stage design to evaluate the combination of Zybrestat, carboplatin and paclitaxel in patients with advanced, platinum-resistant ovarian cancer, a refractory form

The Phase IIa randomized, double-blind, proof-of-concept trial will be conducted in multiple European academic medical centers. The trial will evaluate the antiviral activity, pharmacokinetics, safety and tolerability of

The Phase I portion of the trial is designed to determine the dose-limiting toxicity and maximum tolerated dose (MTD) of ispinesib monotherapy administered as a 1-hour intravenous infusion

A total of 24,050,054 shares of Coley common stock were validly tendered and not withdrawn prior to the expiration of the offer, including 661,444 shares subject to guaranteed